ZINC N-ACETYLTAURINATE 1KG/BAG 98% HIGH PURITY ANTI-AGING

Product DetailsZINC N-ACETYLTAURINATE[CH₃—CO—NH—CH₂—CH₂—SO₃]₂⁻Zn²⁺SPECIFICATIONAPPEARANCE: WHITE TO OFF-WHITE CRYSTALLINE POWDERPURITY: 98% MIN.LOSS ON DRYING: NMT 0.5%RESIDUE ON IGNITION: NMT 0.1%HEAVY METALS(AS Pb): NMT 10PPM.REFERENCE

Zinc N-acetyltaurinate belongs to the family of taurine derivatives having improved neuromuscular activity, which are described in patent FR 2 384 751. It has now been found, surprisingly, that zinc N-acetyltaurinate (ATA-Zn) can be used for preventing and/or treating diseases with lipofuscin accumulation.

Lipofuscin accumulation can be due in particular to aging or to oxidative stress.

Aging is constituted of a collection of functional modifications which gradually decrease the ability of an individual to maintain his or her physiological equilibrium. One of the manifestations of aging is the accumulation, in the tissues, of lipofuscin, which is an autofluorescent, nondegradable substance; it constitutes the major mark of aging.

Oxidative stress (or oxidizing stress) is an attack on the cells and tissues resulting from a dysregulation of the oxidation reactions in the cells, which leads to the formation of toxic substances, such as free radicals (or reactive oxygen species (ROS)). Oxidative stress can affect all tissues and metabolisms, and participate in aging and in a large number of pathological conditions, such as cardiovascular diseases (atherothrombosis), cancers, inflammatory diseases, metabolic diseases (diabetes mellitus, obesity) and degenerative diseases, such as Alzheimer's disease, Parkinson's disease, cataracts or age-related macular degeneration. Age-related macular degeneration (ARMD) is the most common cause of partial-sightedness in industrialized countries among adults over the age of 55. It manifests itself through a thickening of the macular zone of the retina or atrophy of this zone, and sometimes through bleeding (Opthal, Physiol. Opt. 2003, 23:383-399 and Optometry in practice, vol. 5 (2004) 15-32).

Zinc is very concentrated in the ocular tissues, in particular in the retina and in the pigmentary epithelium. It acts as a cofactor for antioxidant enzymes (retinal catalase and dehydrogenase).

Antioxidants, such as vitamins C and E, carotenoids and zinc can limit the risks of progression of age-related macular degeneration.

In particular, it has been demonstrated that zinc plays an important role in maintaining normal ocular functions and that the use of zinc as a food supplement can reduce the aging process in mice (Journal of the American college of nutrition, 2001, vol. 20, No. 2, 106-118). It is also known that zinc appears to have a fundamental role in the prevention of diabetes mellitus and complications thereof. (Li X et al. Diabetes and methallothionein. Mini-Reviews in Medical Chemistry 2007; 7:761-768).

1. Use of zinc N-acetyltaurinate, for the manufacture of a medicament for the prevention and/or treatment of lipofuscin accumulation-related diseases.

2. Use as claimed in claim 1, for the manufacture of a medicament for the prevention and/or treatment of lipofuscin accumulation-related diseases resulting from aging.

3. Use as claimed in claim 1, for the manufacture of a medicament for the prevention and/or treatment lipofuscin accumulation-related diseases resulting from oxidative stress.

4. Use as claimed in any one of claims 1 to 3, for the manufacture of a medicament for the prevention and/or the delaying of age-related macular degeneration and diabetic retinopathy.

5. Use as claimed in any one of claims 1 to 4, characterized in that said N-acetyltaurinate is N-acetyltaurinate dihydrate.

6. Use as claimed in any one of claims 1 to 5, for the manufacture of a medicament for oral administration.

7. Use as claimed in claim 6, for the manufacture of a medicament in the form of gel capsules, sachets, tablets or solutions containing 0.06 to 1 g per unit dose or 0.6 to 5 g/10 ml of solution.

8. Use as claimed in any one of claims 1 to 5, for the manufacture of a medicament for parenteral administration.

9. Use as claimed in claim 8, for the manufacture of a medicament in the form of injectable vials containing 0.1 to 2 g per vial.

10. A pharmaceutical composition for use in preventing and/or treating lipofuscin accumulation-related diseases, characterized in that it contains zinc N-acetyltaurinate as an active ingredient in combination with a pharmaceutically acceptable excipient.

11. The pharmaceutical composition as claimed in claim 10, characterized in that it is provided in the form of gel capsules, sachets, tablets or solutions containing 0.06 to 1 g per unit dose or 0.6 to 5 g/10 ml of solution.

12. The pharmaceutical composition as claimed in claim 10, characterized in that it is provided in the form of injectable vials containing 0.1 to 2 g per vial.

13. Zinc N-acetyltaurinate for use in preventing and/or treating lipofuscin accumulation-related diseases.

14. Zinc N-acetyltaurinate for use in preventing and/or treating lipofuscin accumulation-related diseases resulting from aging.

15. Zinc N-acetyltaurinate for use in preventing and/or treating to lipofuscin accumulation-related diseases resulting from oxidative stress.

16. Zinc N-acetyltaurinate for use in preventing and/or delaying age-related macular degeneration or diabetic retinopathy.